Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Juvisy sur Orge, France Clinical Trials

A listing of Juvisy sur Orge, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (33) clinical trials

Non-opioid Analgesic Combination With Morphine for Postoperative Analgesia.

Since the description of the concept of balanced analgesia in the early 90's, the combination of different analgesic drugs and/or analgesia techniques is part of the standard management of postoperative analgesia. A recent survey conducted in France by Fletcher et al. showed that patients often received one or more NOA ...

Phase

7.82 miles

Learn More »

Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy

Data from a previous single arm study (RESPITE) indicate that transition from PDE5i to riociguat may be feasible, safe and beneficial in patients not adequately responding to PDE5i. REPLACE is a randomized controlled study to confirm the potential clinical benefit of transition from PDE5i to riociguat. Satisfactory clinical response in ...

Phase

8.09 miles

Learn More »

Value of Pharmacokinetic Assays in the Prediction of Induction and Maintenance Therapeutic Response in Crohn's Disease

Vedolizumab (VDZ) is a monoclonal antibody that binds to the heterodimer alpha 4 beta 7 integrin and which has shown its efficacy in Crohn's disease by inducing and maintaining clinical response/remission. The French marketing authorization was obtained for Crohn's disease in patients in failure with anti-TNF (Tumor Necrosis Factor) agents. ...

Phase

8.09 miles

Learn More »

A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension.

To provide riociguat therapy to eligible patients with PAH originating from Bayer-sponsored trials with BAY63-2521/ Riociguat / Adempas who are currently or recently treated in these trials until lack of patient benefit as assessed by investigator, or commercial availability and reimbursement.

Phase

8.2 miles

Learn More »

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.

This is a multi-center, open label, phase IV study to provide continued supply of pasireotide to patients being treated in a current Novartis-sponsored, Oncology CD&MA study and who are benefiting from treatment with pasireotide. Eligible patients are to be consented and can then continue treatment with pasireotide in this protocol. ...

Phase

8.21 miles

Learn More »

Assessment of Intellectual Psychological and Behavioural Developments Between 6 and 9 Years of the Children Born to Hyperthyroid Mothers During Their Pregnancy

INCLUSION CRITERIA : Old from 6 to 9 years included Age of gestation between 37 and <41 weeks of amenorrhoea Born from a mono-foetale pregnancy Euthyrod at the time of the entry in the study Provided education for at the elementary school on a level adapted to its age 2. ...

Phase

8.21 miles

Learn More »

Comparison of Two Strategies of Glucocorticoid Withdrawal in Rheumatoid Arthritis Patients

French multicenter double-blind controlled parallel-group randomized clinical trial Phase IV assessing whether a hydrocortisone replacement therapy could increase the success rate of GC withdrawal at one year, in patients with Rheumatoid Arthritis in low disease activity or remission, in comparison to progressive decrease of GC (GC tapering).

Phase

8.21 miles

Learn More »

A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy

3. STUDY OBJECTIVES 3.1. Primary objective To assess the effect of two withdrawal strategies over two years in patients with stable remission for more than 6 months on combination therapy with infliximab and antimetabolites, and demonstrate that continued combination of infliximab and antimetabolites or continued monotherapy with infliximab are both ...

Phase

8.21 miles

Learn More »

Beta-arrestins and Response to Venlafaxine in Major Depressive Disorder (MDD) (DEPARRESTCLIN)

Rationale: Predictive factors and biomarkers of response to antidepressants in major depressive disorder are scarce. Beta-arrestins are proteins which inhibit G Protein Coupled Receptors and desensitize serotonergic and dopaminergic receptors. Hypothesis: The study hypothesis is that Beta-arrestins 1 and 2 are predictive factors and biomarkers of response to antidepressants in ...

Phase

8.21 miles

Learn More »

A Randomized Multicenter Open Label Study Comparing Early Administration of Azathioprine Plus IFX to Steroids Plus Azathioprine for Acute Severe Colitis

NUMBER OF PATIENTS : 75 patients in each group i.e. a total of 150 patients. RECRUITMENT PERIOD : 24 months STUDY DURATION : 36 months PRIMARY END POINT : Treatment failure is defined by: Absence of steroid-free remission at W52 according to the total Mayo Disease Activity Index score OR ...

Phase

8.21 miles

Learn More »